PE20070015A1 - Proceso para la sintesis de compuestos pirimidinilaminobenzamidas - Google Patents

Proceso para la sintesis de compuestos pirimidinilaminobenzamidas

Info

Publication number
PE20070015A1
PE20070015A1 PE2006000631A PE2006000631A PE20070015A1 PE 20070015 A1 PE20070015 A1 PE 20070015A1 PE 2006000631 A PE2006000631 A PE 2006000631A PE 2006000631 A PE2006000631 A PE 2006000631A PE 20070015 A1 PE20070015 A1 PE 20070015A1
Authority
PE
Peru
Prior art keywords
methyl
alkyl
phenyl
compounds
formula
Prior art date
Application number
PE2006000631A
Other languages
English (en)
Inventor
Joseph Mckenna
Wen-Chung Shieh
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20070015A1 publication Critical patent/PE20070015A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A UN PROCESO DE PREPARACION DE COMPUESTOS DE LA FORMULA (I) DONDE R1 ES ARILO(C6-C14) OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO(C1-C6), FENILO, NITRO, ENTRE OTROS; R2 ES H, ALQUILO(C1-C6) O ARILO(C6-C14); R4 ES H, HALOGENO O ALQUILO(C1-C6); UN COMPUESTO PREFERIDO ES 4-METIL-3-[[4-(3-PIRIDINIL)-2-PIRIMIDINIL]-AMINO]-N-[5-(4-METIL-1H-IMIDAZOL-1-IL)-3-(TRIFLUORO-METIL)-FENIL]-BENZAMIDA. DICHO PROCESO COMPRENDE: A) HACER REACCIONAR EL COMPUESTO DE FORMULA (II) CON EL COMPUESTO DE FORMULA R1-NH-R2 TAL COMO 5-(4-METIL-1H-IMIDAZOL-1-IL)-3-(TRIFLUORO-METIL)-BENCENAMINA, DONDE R3 ES ALQUILO(C1-C6), FENILO OPCIONALMENTE SUSTITUIDO O FENIL-ALQUILO(C1-C6), DICHA REACCION SE CATALIZA CON UNA BASE TAL COMO HIDRURO DE METAL, BIS-(TRIMETIL-SILIL)-AMIDA DE METAL, DIALQUIL-AMIDA DE LITIO, TERBUTOXIDO DE POTASIO, ENTRE OTROS, EN UN SOLVENTE ORGANICO TAL COMO TETRAHIDROFURANO, DIMETIL-FORMAMIDA, TOLUENO O N-METIL-PIRROLIDONA. EL PROCESO SE LLEVA A CABO A UNA TEMPERATURA DE -50°C A 50°C. DICHOS COMPUESTOS SON INHIBIDORES DE QUINASAS DE TIROSINA SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES NEOPLASICAS TAL COMO LEUCEMIA
PE2006000631A 2005-06-09 2006-06-07 Proceso para la sintesis de compuestos pirimidinilaminobenzamidas PE20070015A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68897705P 2005-06-09 2005-06-09
US70559005P 2005-08-04 2005-08-04

Publications (1)

Publication Number Publication Date
PE20070015A1 true PE20070015A1 (es) 2007-02-06

Family

ID=37091153

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000631A PE20070015A1 (es) 2005-06-09 2006-06-07 Proceso para la sintesis de compuestos pirimidinilaminobenzamidas

Country Status (32)

Country Link
US (2) US8124763B2 (es)
EP (1) EP1924574B1 (es)
JP (1) JP5118024B2 (es)
KR (3) KR101514593B1 (es)
AR (1) AR053890A1 (es)
AT (1) ATE487709T1 (es)
AU (1) AU2006258051B2 (es)
BR (1) BRPI0611663A2 (es)
CA (1) CA2610105C (es)
CY (1) CY1111428T1 (es)
DE (1) DE602006018156D1 (es)
DK (1) DK1924574T3 (es)
EC (1) ECSP077982A (es)
EG (1) EG25039A (es)
GT (1) GT200600217A (es)
HK (1) HK1117524A1 (es)
IL (1) IL187421A (es)
JO (1) JO2636B1 (es)
MA (1) MA29599B1 (es)
MX (1) MX2007015423A (es)
MY (1) MY147436A (es)
NO (1) NO340743B1 (es)
NZ (1) NZ563740A (es)
PE (1) PE20070015A1 (es)
PL (1) PL1924574T3 (es)
PT (1) PT1924574E (es)
RU (1) RU2444520C2 (es)
SA (1) SA06270147B1 (es)
SI (1) SI1924574T1 (es)
TN (1) TNSN07463A1 (es)
TW (1) TWI430999B (es)
WO (1) WO2006135641A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
US8242271B2 (en) 2007-06-04 2012-08-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
EP2305667A3 (en) 2008-07-17 2011-05-11 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
EP2530081A3 (en) 2008-11-05 2013-04-10 Teva Pharmaceutical Industries, Ltd. Nilotinib HCI crystalline forms
WO2010060074A1 (en) * 2008-11-24 2010-05-27 Teva Pharmaceutical Industries Ltd. Preparation of nilotinib and intermediates thereof
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
JP5841234B2 (ja) 2011-03-31 2016-01-13 ザ プロクター アンド ギャンブルカンパニー フケ／脂漏性皮膚炎の治療に有効な皮膚活性剤を特定及び評価するためのシステム、モデル、及び方法
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2013120852A1 (en) 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
US9920357B2 (en) 2012-06-06 2018-03-20 The Procter & Gamble Company Systems and methods for identifying cosmetic agents for hair/scalp care compositions
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
CN103694176B (zh) 2014-01-07 2015-02-18 苏州立新制药有限公司 尼洛替尼中间体的制备方法
EP3095782A1 (en) 2015-05-18 2016-11-23 Esteve Química, S.A. New method for preparing 3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)benzenamine
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
JP7409696B2 (ja) 2018-06-15 2024-01-09 ハンダ ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤の塩およびその組成物
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136082A (en) * 1990-08-03 1992-08-04 Himont Incorporated Process for preparing organic esters and amides and catalyst system therefor
CA2151491A1 (en) 1992-12-24 1994-07-07 Robert J. Kaufman Fluorocarbon emulsions
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5597829A (en) 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
AR013261A1 (es) 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
US20030059465A1 (en) 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
US6395916B1 (en) 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
DE69901379T2 (de) 1999-03-09 2002-11-07 Sigma Tau Ind Farmaceuti Camptothecin-Derivate mit Antitumor-Wirkung
IT1306129B1 (it) 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
DE19926056B4 (de) 1999-06-08 2004-03-25 Gkss-Forschungszentrum Geesthacht Gmbh Einrichtung zur Analyse atomarer und/oder molekularer Elemente mittels wellenlängendispersiver, röntgenspektrometrischer Einrichtungen
GB9918885D0 (en) 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US20040009229A1 (en) 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
US20020150615A1 (en) 2001-02-12 2002-10-17 Howard Sands Injectable pharmaceutical composition comprising microdroplets of a camptothecin
US6653319B1 (en) 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
US6629598B2 (en) 2001-08-10 2003-10-07 Vinod K. Narula Flexible ribbed splint system
CA2461556A1 (en) 2001-10-15 2003-04-24 Crititech, Inc. Compositions and methods for delivery of microparticles of poorly water soluble drugs and methods of treatment
US20060078618A1 (en) 2001-12-11 2006-04-13 Constantinides Panayiotis P Lipid particles and suspensions and uses thereof
JP2003267891A (ja) 2002-03-13 2003-09-25 Mitsubishi-Kagaku Foods Corp Ｗ／ｏ／ｗ型エマルション製剤
FR2840303B1 (fr) 2002-05-31 2005-07-15 Rhodia Chimie Sa Procede d'arylation ou de vinylation ou d'alcylynation d'un compose nucleophile
CZ294371B6 (cs) 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
EP1393719A1 (en) 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
JP4426749B2 (ja) 2002-07-11 2010-03-03 株式会社産学連携機構九州 Ｏ／ｗ型エマルション製剤
US20040171560A1 (en) 2002-12-23 2004-09-02 Dabur Research Foundation Stabilized pharmaceutical composition
JP2006199590A (ja) 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
WO2005042539A1 (en) 2003-10-29 2005-05-12 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
WO2005060871A1 (en) 2003-12-17 2005-07-07 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of camptothecins and process for making same
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos

Also Published As

Publication number Publication date
JP5118024B2 (ja) 2013-01-16
MX2007015423A (es) 2008-02-21
ECSP077982A (es) 2008-01-23
DE602006018156D1 (de) 2010-12-23
JP2008545786A (ja) 2008-12-18
TNSN07463A1 (en) 2009-03-17
PT1924574E (pt) 2011-02-08
DK1924574T3 (da) 2011-02-14
KR101514593B1 (ko) 2015-04-22
KR20080022093A (ko) 2008-03-10
CY1111428T1 (el) 2015-08-05
WO2006135641A3 (en) 2007-03-29
GT200600217A (es) 2007-03-28
EP1924574A2 (en) 2008-05-28
MY147436A (en) 2012-12-14
EP1924574B1 (en) 2010-11-10
NO340743B1 (no) 2017-06-12
BRPI0611663A2 (pt) 2010-09-28
NZ563740A (en) 2011-03-31
MA29599B1 (fr) 2008-07-01
AU2006258051B2 (en) 2010-09-09
EG25039A (en) 2011-07-06
AR053890A1 (es) 2007-05-23
PL1924574T3 (pl) 2011-04-29
IL187421A0 (en) 2008-02-09
CA2610105A1 (en) 2006-12-21
WO2006135641A2 (en) 2006-12-21
SI1924574T1 (sl) 2011-02-28
US20120116081A1 (en) 2012-05-10
KR20130118394A (ko) 2013-10-29
CA2610105C (en) 2014-03-25
US8124763B2 (en) 2012-02-28
HK1117524A1 (en) 2009-01-16
KR20120066067A (ko) 2012-06-21
AU2006258051A1 (en) 2006-12-21
SA06270147B1 (ar) 2009-12-22
RU2007148231A (ru) 2009-07-20
TWI430999B (zh) 2014-03-21
NO20080157L (no) 2008-01-09
US8946416B2 (en) 2015-02-03
JO2636B1 (en) 2012-06-17
ATE487709T1 (de) 2010-11-15
TW200726756A (en) 2007-07-16
IL187421A (en) 2011-11-30
RU2444520C2 (ru) 2012-03-10
KR101216249B1 (ko) 2012-12-28
US20080188656A1 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
PE20070015A1 (es) Proceso para la sintesis de compuestos pirimidinilaminobenzamidas
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
TW200726754A (en) Chemical process
TW200716563A (en) Process for the synthesis of organic compounds
RU2009132186A (ru) Способ получения соединений 2-аминотиазола в качестве ингибиторов киназы
MX2007006630A (es) Metodo para preparar n-fenilpirazol-1-carboxamidas.
MX2010001773A (es) Metodo para preparar derivados de 5-haloalquil-4,5-dihidroisoxasol .
AR053662A1 (es) Compuestos de pirazol inhibidores de la actividad quinasa cdk y gsk
SG158864A1 (en) Processes for preparing 4-(phenoxy-5-methyl-pyrimidin-4-yloxy)piperidine-1- carboxylic acid derivatives and related compounds
NZ611898A (en) Compounds for inhibiting mitotic progression
WO2007149448A3 (en) Pyrazinones as cellular proliferation inhibitors
AR048875A1 (es) Un proceso para preparar montelukast y compuestos intermedios para el mismo
PE20070829A1 (es) Inhibidores cetp heterociclicos
ITMI20041566A1 (it) "trpv1 agonisti, formulazioni che li contengono e loro usi"
CN101068770B (zh) 制备6-取代的-1-甲基-1-h-苯并咪唑衍生物的方法及其合成中间体
ZA201003751B (en) Process for the synthesis of propargylated aminoindan derivatives
EP2195395A4 (en) NEW ORGANIC FLUORESCENT SULFONYL HARVEST BENZOXAZINONE PIGMENTS
ATE555088T1 (de) Verfahren zur herstellung einer heterocyclischen mercaptoverbindung
PE20060421A1 (es) Procedimiento para preparar un compuesto de pirrolotriazina anilina como inhibidores de cinasa
JP2020513008A (ja) シクロプロピルアルキルアミン及びその調製方法
CY1114798T1 (el) Ενωσεις σουλφοναμιδιου για τη θεραπευτικη αντιμετωπιση αναπνευστικων διαταραχων
TW200635940A (en) Process for preparing thiophene-glycoside derivatives
MX2010004168A (es) Procedimiento mejorado para preparar 2-(fenil sustituido)-2-hidroxi-etil carbamatos.
KR20170035917A (ko) 피리미딘-1-올 화합물의 제조 방법, 및 이의 중간체
AR062623A1 (es) Proceso quimico

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed